This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cardiomyopathy in Diseases Classified Elsewhere달리 분류된 질환에서의 심근병증 (타분류질환의 심근병증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I43 (cardiomyopathy in diseases classified elsewhere) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsInfiltrative cardiomyopathy, amyloid cardiomyopathy, cardiac hemochromatosis, cardiac involvement in glycogen storage disease, Fabry disease cardiomyopathy, secondary cardiomyopathy
C. Adult onsetAppears as myocardial infiltration or damage during the course of an underlying systemic metabolic disease. ATTR amyloidosis is diagnosed mainly in men aged 60 and over, and AL amyloidosis around the 60s.
1. HistoryHistory of recognition of cardiac amyloidosis; development of a transthyretin stabilizer (tafamidis) (2019); history of enzyme replacement therapy for Fabry disease
2. CausesAmyloidosis (ATTR, AL), Fabry disease (GLA variants), hemochromatosis (HFE variants), glycogen storage disease (GSD II, III), Gaucher disease, Wilson disease
3. GeneticshATTR: TTR gene variants (V122I, V30M, etc.); Fabry disease: GLA gene (X-linked); hemochromatosis: HFE C282Y; glycogen storage: GAA gene
4. General epidemiologyATTR amyloidosis is an important cause of heart failure and HFpEF in older people; Fabry disease prevalence 1/40,000–117,000; cardiac hemochromatosis with HFE C282Y homozygosity
5. PathophysiologyExtracellular deposition of amyloid fibrils → myocardial stiffness and toxicity; excess iron and copper deposition → oxidative damage; glycosylceramide deposition → cellular dysfunction
6. SymptomsReduced exercise tolerance, dyspnea (HFpEF pattern), leg edema, syncope, arrhythmias; symptoms of systemic infiltration (peripheral neuropathy, reduced kidney function)
7. SignsDiminished heart sounds, S4 gallop, signs of right heart failure (ascites, hepatomegaly), peripheral edema; Fabry angiokeratomas of the skin; amyloid macroglossia
8. ScreeningAmyloid screening in older men with HFpEF (technetium scintigraphy, serum FLC); GLA enzyme activity testing when Fabry disease is suspected
9. DiagnosisCardiac MRI (subendocardial or transmural LGE), technetium scintigraphy (ATTR), serum/urine protein electrophoresis, tissue biopsy
10. TreatmentATTR: tafamidis (TTR stabilization), patisiran/vutrisiran (RNA interference); AL: collaboration with hematology-oncology; Fabry: ERT; hemochromatosis: phlebotomy
11. PrognosisMedian survival 6–12 months (before treatment) with cardiac involvement in AL amyloidosis; prognosis of ATTR improved with tafamidis treatment; early treatment is key
12. PreventionGenetic testing of first-degree relatives of patients with familial ATTR; prevention of cardiac damage with early phlebotomy in hemochromatosis; newborn screening for Fabry disease
13. ReferencesMaurer MS et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy … and 9 other papers

1. History

The history of cardiomyopathy in diseases classified elsewhere reflects the discovery of each causal metabolic disease and the development of recognition of its cardiac involvement. Cardiac involvement in amyloidosis was first described in the 19th century by Rokitansky and Virchow, but the chemical nature and types of amyloid proteins began to be elucidated only in the mid-to-late 20th century. Transthyretin (TTR) was shown in the 1980s to be the precursor protein of amyloid fibrils, and confirmation that wild-type TTR (wild-type ATTR, wtATTR) causes senile systemic amyloidosis is relatively recent.

The history of TTR stabilization therapy reached a new turning point in 2019 when tafamidis was shown in the ATTR-ACT trial to significantly reduce mortality and hospitalization in patients with cardiac amyloidosis. It was the first oral drug to demonstrate improved survival in ATTR cardiomyopathy, and clinical interest in this disease subsequently increased explosively. In 2022–2023, results of clinical trials showing improved cardiac outcomes with RNA interference drugs (patisiran, vutrisiran) in hATTR amyloidosis were published.

Fabry disease was first described by Johannes Fabry in 1898, and its association with the GLA gene (α-galactosidase A) was revealed in 1967. With the approval in 2001 of enzyme replacement therapy (ERT) with agalsidase beta, it became possible to suppress the progression of Fabry disease cardiomyopathy. Cardiac involvement in hereditary hemochromatosis has been recognized since the mid-20th century, and in 1996 the HFE gene (C282Y, H63D variants) was shown to be the most common cause. Since it was established that early phlebotomy can prevent myocardial iron deposition, the importance of early diagnosis has been emphasized.


2. Causes

Cardiomyopathies classified under ICD I43 are caused by various systemic metabolic or infiltrative diseases. Amyloid cardiomyopathy has two main types. Transthyretin amyloidosis (ATTR) is divided into wild-type (wtATTR, senile systemic amyloidosis) and hereditary (hATTR, TTR gene variants), and in both the TTR protein deposits in the myocardium through misfolding and fibril formation. In AL amyloidosis (primary systemic amyloidosis), monoclonal light chain proteins produced by plasma cell disorders (multiple myeloma, MGUS) form amyloid fibrils and deposit.

Fabry disease is an X-linked recessive lysosomal storage disease in which GLA gene variants cause deficiency of the α-galactosidase A enzyme, so that glycosylceramide (Gb3) accumulates in cardiomyocytes, vascular endothelium, renal glomerular cells and elsewhere. In hereditary hemochromatosis, mainly due to homozygous HFE C282Y variants, intestinal iron absorption increases excessively and iron deposits in the myocardium, liver, pancreas, joints and elsewhere. Among glycogen storage diseases, Pompe disease (GSD II, GAA gene variants) and GSD III (AGL variants) show a hypertrophic cardiomyopathy phenotype due to excessive myocardial glycogen accumulation. In Wilson disease, abnormal copper metabolism (ATP7B gene variants) causes copper to accumulate in various organs including the myocardium, and cardiomyopathy rarely develops.


3. Genetics

In cardiomyopathy in diseases classified elsewhere, genetic factors vary with the underlying disease. Hereditary ATTR (hATTR) amyloidosis is an autosomal dominant disease caused by pathogenic variants of the TTR gene. More than 100 pathogenic variants are known; the Val122Ile (V122I) variant occurs at high frequency (about 3–4%) in African Americans and causes senile cardiomyopathy. The Val30Met (V30M) variant occurs at high frequency in Portugal, Sweden and Japan and causes peripheral neuropathy + cardiomyopathy. Fabry disease shows an X-linked recessive inheritance pattern, with the classic form in hemizygous males and variable expression from mild to classic forms in heterozygous females.

The most common genetic form of hereditary hemochromatosis is HFE C282Y/C282Y homozygosity, which occurs at high frequency (about 0.5%) in Northern European Caucasians. H63D heterozygosity or C282Y/H63D compound heterozygosity can also cause mild hemochromatosis. Pompe disease (GSD II) is due to autosomal recessive variants of the GAA gene and is divided into an infantile form (severe cardiac hypertrophy) and a late-onset form (mainly skeletal muscle involvement). Genetic testing is essential for confirmation of each disease and family screening, and newborn screening is being introduced in some countries.


4. General epidemiology

The epidemiology of cardiomyopathy in diseases classified elsewhere differs with the underlying disease. ATTR amyloidosis was once considered rare, but recent advances in diagnostic technology (99mTc-DPD/PYP scintigraphy) are revealing that its actual prevalence is much higher. wtATTR is known to be so common that cardiac involvement is found at autopsy in about 25% of people aged 80 and over. About 10–15% of older patients with heart failure with preserved ejection fraction (HFpEF) are estimated to have ATTR amyloid cardiomyopathy. The annual incidence of AL amyloidosis is about 8–10 per million population, and prognosis is markedly poor when there is cardiac involvement.

The prevalence of Fabry disease is about 1 per 40,000–117,000 population, and studies using newborn screening report higher prevalence. Fabry disease is known to account for about 2–3% of left ventricular hypertrophy of unknown cause and about 4–6% of cases misdiagnosed as HCM. In hereditary hemochromatosis, cardiac involvement (cardiomyopathy, arrhythmias) appears mainly in patients with severe iron overload, and cardiac complications occur in about 15–30% of inadequately treated HFE C282Y homozygous patients.


5. Pathophysiology

The pathophysiology of amyloid cardiomyopathy is understood in two steps. First, protein misfolding forms amyloid fibrils with a beta-sheet (β-sheet) structure. In ATTR, tetrameric TTR dissociates into monomers and misfolds, while in AL, monoclonal light chains produced by plasma cells form fibrils directly. Second, the fibrils deposit in the extracellular matrix, increasing the structural stiffness of the myocardium, and at the same time the amyloid fibrils themselves exert direct cardiomyocyte toxicity (intracellular calcium imbalance, oxidative stress, mitochondrial dysfunction, apoptosis). As a result, a restrictive cardiomyopathy phenotype with prominent diastolic dysfunction appears.

In Fabry disease cardiomyopathy, GLA enzyme deficiency causes Gb3 (globotriaosylceramide) to accumulate in the lysosomes of cardiomyocytes, vascular smooth muscle and conduction system cells. Gb3 accumulation causes lysosomal dysfunction, impaired autophagy, oxidative stress and cell death. Myocardial hypertrophy (mainly of the left ventricle, especially the inferolateral wall) progresses, and myocardial fibrosis develops in later stages. In hemochromatosis cardiomyopathy, when excess iron accumulates in cardiomyocytes, reactive oxygen species (ROS) are generated through the Fenton reaction, damaging cell membranes, mitochondria and DNA. Iron accumulation also suppresses cardiomyocyte function and promotes fibrosis, progressing to a dilated or restrictive cardiomyopathy phenotype.


6. Symptoms

Symptoms of cardiomyopathy in diseases classified elsewhere combine those of myocardial dysfunction and the underlying systemic disease. In amyloid cardiomyopathy, progressive decline in exercise tolerance, dyspnea (a heart failure with preserved ejection fraction pattern) and fatigue are the main symptoms. Severe diastolic dysfunction reduces cardiac output, and orthostatic hypotension commonly accompanies it because of autonomic amyloid involvement. Syncope or palpitations are due to sinus node dysfunction, atrioventricular block or atrial fibrillation. Systemic amyloid symptoms include peripheral neuropathy (numbness, pain), reduced kidney function (proteinuria), carpal tunnel syndrome (a common prodromal symptom especially in hATTR) and a flaccid bowel.

In Fabry disease, extremity pain (acroparesthesia), heat intolerance and cutaneous angiokeratomas appear early, and with progression into adulthood, reduced exercise tolerance, palpitations (myocardial hypertrophy, arrhythmias) and stroke occur. In hemochromatosis cardiomyopathy, fatigue, reduced exercise tolerance, palpitations (arrhythmias) and heart failure symptoms appear, accompanied by skin pigmentation (bronze), diabetes and liver function abnormalities. In Pompe disease (adult form), skeletal and respiratory muscle weakness is more prominent than cardiomyopathy, whereas severe hypertrophic cardiomyopathy is characteristic of the infantile form.


7. Signs

On physical examination in amyloid cardiomyopathy, heart sounds are diminished, and an S4 gallop due to impaired relaxation may be heard at the apex. Low voltage on the ECG despite left ventricular hypertrophy is a characteristic finding of ATTR and AL amyloid cardiomyopathy (discordance between hypertrophy on echocardiography and low voltage on ECG). As right heart failure progresses, elevated jugular venous pressure, hepatomegaly, ascites and leg edema appear. In AL amyloidosis, characteristic skin lesions such as macroglossia, periorbital purpura and swelling of the fingers and toes may be observed.

In patients with Fabry disease, cutaneous angiokeratomas (angiokeratoma corporis diffusum; small reddish-purple papules in the umbilical-lumbar region) are characteristic. Cornea verticillata is the typical ophthalmologic finding of Fabry disease seen on slit-lamp examination. In hemochromatosis, bronze skin pigmentation, hepatomegaly and joint swelling may be present. In all cases, pulmonary edema (crackles), jugular venous distension and peripheral edema appear as heart failure progresses.


8. Screening

Screening for cardiomyopathy in diseases classified elsewhere consists of recognizing the underlying disease and screening for cardiac involvement. To screen for ATTR amyloid cardiomyopathy, echocardiography + ECG (for low voltage) + 99mTc-DPD or PYP bone scan is performed in high-risk groups (older men, HFpEF, asymmetric left ventricular hypertrophy, recurrent carpal tunnel syndrome, postural orthostatic hypotension). Serum and urine protein electrophoresis (SPEP, UPEP) and free light chain (FLC) measurement are essential to exclude AL amyloidosis.

Fabry disease is screened for in patients with left ventricular hypertrophy of unknown cause by alpha-galactosidase A enzyme activity (men) and GLA genetic testing (women). Hemochromatosis is screened for with serum ferritin and transferrin saturation tests and confirmed by HFE genetic testing. Family screening through genetic testing and iron metabolism tests in first-degree relatives is recommended. Pompe disease is diagnosed by acid alpha-glucosidase (GAA) enzyme activity testing and GAA genetic testing.


9. Diagnosis

Cardiac MRI is central to diagnosing infiltrative cardiomyopathy. In amyloid cardiomyopathy, a characteristic pattern of diffusely distributed subendocardial or transmural LGE is observed, together with global elevation on T1 mapping and a markedly increased extracellular volume fraction (ECV). In Fabry disease, mid-wall LGE mainly at the basal inferolateral wall and reduced T1 mapping (due to Gb3 deposition) are characteristic. 99mTc-DPD/PYP bone scan is an important test that can confirm ATTR amyloid cardiomyopathy noninvasively; with negative blood monoclonal protein tests + Grade 2–3 myocardial uptake, ATTR can be confirmed without biopsy. Amyloidosis can be confirmed when apple-green birefringence is observed under polarized light microscopy after Congo red staining of a tissue biopsy (myocardium, abdominal fat, gingiva). TTR immunostaining differentiates ATTR from AL. In hemochromatosis, iron overload is confirmed by liver biopsy or MRI-based liver iron quantification.


10. Treatment

The TTR-stabilizing drug tafamidis brought about innovation in the treatment of ATTR amyloid cardiomyopathy. In the 2019 ATTR-ACT trial, tafamidis (61 mg or 20 mg/day) reduced mortality and cardiovascular hospitalization by about 30% compared with placebo. The RNA interference drugs patisiran (FDA approved 2018, hATTR polyneuropathy) and vutrisiran (approved 2022) target TTR mRNA to reduce hepatic TTR production, and improved cardiac outcomes are also being reported. AL amyloidosis is managed with hematology-oncology to treat the underlying plasma cell disorder (chemotherapy as for multiple myeloma, autologous hematopoietic stem cell transplantation). GDMT for heart failure is applied cautiously because its use may be limited in amyloid patients prone to hypotension.

In Fabry disease, enzyme replacement therapy (ERT: agalsidase alfa or beta) to restore GLA enzyme activity has been used clinically since 2001 and suppresses myocardial hypertrophy and symptom progression. Chaperone therapy (migalastat) is an orally administered alternative for patients with specific susceptible GLA variants. Treatment of hemochromatosis cardiomyopathy is iron removal by phlebotomy. Removing myocardial iron deposits with regular phlebotomy (ferritin target 50–100 μg/L) can improve cardiomyopathy, with a greater effect especially when treatment is early. In all cases, GDMT for heart failure and treatment of arrhythmias are given concurrently.


11. Prognosis

The prognosis of cardiomyopathy in diseases classified elsewhere depends greatly on the type and severity of the underlying disease, timing of diagnosis and whether it is treated. AL amyloid cardiomyopathy has such a poor prognosis that median survival before treatment is only 6–12 months. In the Mayo staging system (based on NT-proBNP, troponin I and FLC levels), the high-risk group (Stage IV) has a 1-year survival of less than about 30%. Prognosis is improving with modern chemotherapy (bortezomib-based regimens, autologous transplantation).

The prognosis of ATTR amyloid cardiomyopathy is relatively better than that of AL, but without treatment, NYHA functional decline and hospitalizations recur. Tafamidis treatment has been shown to reduce 30-month mortality by about 30%. In Fabry disease, ERT can slow myocardial hypertrophy and symptom progression, but once myocardial fibrosis has progressed it is irreversible. Early diagnosis and treatment are the key determinants of prognosis. In hemochromatosis cardiomyopathy, cardiac function can recover substantially if phlebotomy is started at a stage when iron deposition is not severe.


12. Prevention

To prevent ATTR amyloid cardiomyopathy, it is important to perform genetic testing in first-degree relatives of patients with familial hATTR and to screen carriers of pathogenic TTR variants regularly for cardiac involvement. Studies are emerging showing that starting tafamidis or RNA interference therapy early can prevent progression of myocardial deposition, and research on when to begin preventive treatment in asymptomatic carriers is under way.

In Fabry disease, myocardial damage can be prevented by starting ERT after early diagnosis through newborn screening programs. Some countries are introducing Fabry disease into the newborn screening panel. In hereditary hemochromatosis, regular monitoring of ferritin and transferrin saturation and timely phlebotomy are key to preventing cardiac damage. When there is a family history of HFE C282Y homozygosity, siblings undergo HFE genetic testing. In families with glycogen storage diseases, including Pompe disease (adult form), family screening through genetic counseling and genetic testing is also recommended.


13. References

  1. Maurer MS, Schwartz JH, Gundapaneni B, et al. (ATTR-ACT Study Investigators). Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine. 2018;379(11):1007-1016. DOI: 10.1056/NEJMoa1805689. PMID: 30145929.

  2. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-2412. DOI: 10.1161/CIRCULATIONAHA.116.021612. PMID: 27143678.

  3. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021;42(16):1554-1568. DOI: 10.1093/eurheartj/ehab072. PMID: 33787905.

  4. Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure. 2020;22(7):1076-1096. DOI: 10.1002/ejhf.1960. PMID: 32654350.

  5. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology. 2016;68(12):1323-1341. DOI: 10.1016/j.jacc.2016.06.053. PMID: 27634121.

  6. Briani C, Cavallaro T, Lauria G. Hereditary transthyretin amyloidosis: an update. Orphanet Journal of Rare Diseases. 2016;11(1):93. DOI: 10.1186/s13023-016-0469-9. PMID: 27405672.

  7. Aimo A, Camerini L, Barison A, et al. The Role of Cardiac Magnetic Resonance in the Evaluation and Management of Infiltrative Cardiomyopathies. Cardiac Failure Review. 2021;7:e01. DOI: 10.15420/cfr.2020.29. PMID: 33680516.

  8. van Dalen FJ, Ter Horst IKN, Geerts BF, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States. JACC: Heart Failure. 2020;8(10):819-827. DOI: 10.1016/j.jchf.2020.07.005. PMID: 32861823.

  9. Adams PC, Barton JC. Haemochromatosis. Lancet. 2007;370(9602):1855-1860. DOI: 10.1016/S0140-6736(07)61782-6. PMID: 18061062.

  10. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. New England Journal of Medicine. 2010;362(15):1396-1406. DOI: 10.1056/NEJMoa0909859. PMID: 20393176.